OrthoPediatrics Corp. (KIDS) β€” RQD Stock Rating Cockpit

$31.52 +2.34% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $31.59

OrthoPediatrics Corp. (KIDS) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $823.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KIDS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is KIDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, OrthoPediatrics Corp. (NASDAQ: KIDS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $31.52 (+2.34% 1D, market cap $823.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KIDS ranks #294 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does KIDS compare to BBNX and IART in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), KIDS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 73.1%, and ROIC of -7.3%. By comparison, BBNX (Beta Bionics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -22.1%, cap $955.8M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $998.2M). Among the 5-stock peer group, KIDS leads on earnings multiple (N/A) while KIDS leads on capital efficiency (-7.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KIDS?
β–Ό

Per KIDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425450), OrthoPediatrics Corp. generated $236.3M in revenue (+15.4% YoY), -$39.6M in net income, and -$16.0M in free cash flow against $508.6M in total assets and $99.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $31.59 (+0.23%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY β€’ 49.3% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510050
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D Β· Rk D+
Cash (9)Whales (16)SEC (12)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
$36 Bull$30 Base$24 Bear
πŸ“¬ FREE KIDS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for KIDS)Realized 20D OHLCV Swing Band: Β±10.4%
Deterministic 5-Pillar Attribution (50/100 Composite)
πŸ” WHY KIDS SCORES 50/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (32% of score)

20D Institutional Volume Accumulation (Β±10.4% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (24% of score)

Altman Z-Score 3.00 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
42
Grade D$22.08-0.2% Next Q
Q2 (-2Q)
45
Grade D$22.03+9% Next Q
Q3 (-1Q)
47
Grade D$24.02+31.2% Next Q
Current
50
Grade D$31.52-1.4% Hist 90D Ξ±
Trajectory: D (42) β†’ D (50)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a KIDS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While KIDS currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.44) and Max Pain ($33.10) forces dealer call-delta covering toward $35.86.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KIDSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œKIDS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMOVERBOUGHT (>70)
7930 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE94% OF RANGE
L: $14$31.52H: $33
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on KIDS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-7.3% ROIC with 73.1% gross margin and -1.94% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 3.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (48)

19/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like KIDS
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KIDS)

  • βœ“Walkthrough of KIDS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KIDS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +99.75%⚑ TESTING RESISTANCE
2026-11-02O $30.80H $31.52L $30.80C $31.52VOL 835.0K
RES: $32.86SUP: $22.20SMA50: $23.44SMA200: $19.63
$33.82$28.86$23.89$18.93$13.97RES $32.86SUP $22.20$31.522026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KIDS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KIDS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for KIDS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KIDS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KIDS)

1. Head-to-Head Health Care Peer Comparison (KIDS vs. BBNX, IART, SIBN, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OrthoPediatrics Corp. (KIDS) ranks #294 by composite RQD confidence (50/100, grade D) and #382 by equity capitalization ($823.0M). Within this direct 5-issuer industry benchmark cohort, KIDS leads on earnings valuation at N/A trailing P/E, while KIDS leads on capital efficiency and profitability with -7.3% ROIC and 73.1% gross margin. SIBN currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with KIDS at 50/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KIDS ACTIVE
OrthoPediatrics Corp.
D 50/100 β€” 73.1% -7.3% +2.34% $823.0M Benchmark Subject
BBNX
Beta Bionics Inc.
D- 39/100 β€” 55.4% -22.1% -1.51% $955.8M /bbnx-vs-kids β†’
IART
Integra LifeSciences Holdings Corporation
E 20/100 β€” 50.9% -35.0% +4.82% $998.2M /iart-vs-kids β†’
SIBN
SI-BONE Inc.
D+ 53/100 β€” 79.6% -10.3% +2.66% $1.00B /sibn-vs-kids β†’
SGP
SpyGlass Pharma Inc.
D- 43/100 β€” β€” -35.0% -1.06% $1.09B /sgp-vs-kids β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001425450

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OrthoPediatrics Corp. (KIDS) reported GAAP revenue of $236.3M (+15.4% vs. FY2024 revenue of $204.7M , and +58.9% cumulative change since FY2023) , GAAP net income of -$39.6M, operating cash flow of -$4.9M, and free cash flow of -$16.0M (+61.4% YoY). On the balance sheet, KIDS closed FY2025 with $508.6M in total assets against $99.8M in total debt (Altman Z-Score: 3.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $236.3M -$39.6M -$4.9M -$16.0M $508.6M $99.8M
FY2024 (FY) 2024-12-31 $204.7M -$37.8M -$27.0M -$41.3M $473.2M $73.0M
FY2023 (FY) 2023-12-31 $148.7M -$21.0M -$27.0M -$27.0M β€” β€”

3. KIDS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KIDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, OrthoPediatrics Corp. (NASDAQ: KIDS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $31.52 (+2.34% 1D, market cap $823.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KIDS ranks #294 in composite RQD confidence.

How does KIDS compare to BBNX and IART in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KIDS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 73.1%, and ROIC of -7.3%. By comparison, BBNX (Beta Bionics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -22.1%, cap $955.8M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $998.2M). Among the 5-stock peer group, KIDS leads on earnings multiple (N/A) while KIDS leads on capital efficiency (-7.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KIDS?

Per KIDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425450), OrthoPediatrics Corp. generated $236.3M in revenue (+15.4% YoY), -$39.6M in net income, and -$16.0M in free cash flow against $508.6M in total assets and $99.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KIDS trading relative to its 50-day, 200-day, and 52-week technical levels?

KIDS last traded at $31.52 (+2.34% on volume of 835,010 shares), positioning the stock +34.47% above its 50-day simple moving average ($23.44) and +60.57% above its 200-day simple moving average ($19.63). Across its 52-week range of $14.42 to $32.62, KIDS sits at the 94.0% percentile with a 14-day RSI of 79.0 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±10.4% ($28.24 to $34.80).

KIDS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell KIDS stock right now?

OrthoPediatrics Corp. (KIDS) currently earns a Roarable Rating of D (Sell β€” SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.

What is KIDS's 12-month price target and RQD AI Jury consensus?

KIDS's 12-month base price target is $30.39 (range $23.7 to $35.86), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%